H.C. Wainwright initiated coverage on Celularity with a new price target
$CELU
Biotechnology: Pharmaceutical Preparations
Health Care
H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/30/2023 | $5.00 → $1.00 | Equal-Weight → Underweight | Morgan Stanley |
| 12/22/2022 | Outperform → Perform | Oppenheimer | |
| 6/22/2022 | $15.00 | Buy | H.C. Wainwright |
| 4/6/2022 | $10.00 | Buy → Hold | Truist |
| 1/28/2022 | $9.00 | Outperform | Oppenheimer |
| 11/24/2021 | $9.00 | Equal-Weight | Morgan Stanley |
| 10/19/2021 | $12.00 | Buy | Truist Securities |
8-K - Celularity Inc (0001752828) (Filer)
8-K - Celularity Inc (0001752828) (Filer)
NT 10-Q - Celularity Inc (0001752828) (Filer)
FLORHAM PARK, N.J. and ORLANDO, Fla., June 04, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, and Fountain Life Management, LLC ("Fountain Life"), a leading healthy longevity company delivering a next-generation preventive health model through advanced diagnostics, restorative therapeutics, and AI-driven health intelligence, today announced the availability of cenplacel-L, a placental-derived allogeneic investigational cell therapy, for investigational use by licensed physicians in the State of Florida under recently enacted legislation supporting responsi
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular therapies, today announced that it has posted a Letter to Shareholders from Robert J. Hariri, M.D., Ph.D., Celularity's Founder, Chairman, and Chief Executive Officer, to the Investor Relations section of its website. The letter is also included below. Dear Fellow Shareholders, I want to take this opportunity to provide an important update on the developments at Celularity over the past several months particularly in the context of evolving clinical and regulatory progress.
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder. "Rick's appointment comes at an important time for Celularity as we conti
3 - Celularity Inc (0001752828) (Issuer)
3 - Celularity Inc (0001752828) (Issuer)
3 - Celularity Inc (0001752828) (Issuer)
Morgan Stanley downgraded Celularity from Equal-Weight to Underweight and set a new price target of $1.00 from $5.00 previously
Oppenheimer downgraded Celularity from Outperform to Perform
H.C. Wainwright initiated coverage of Celularity with a rating of Buy and set a new price target of $15.00
4 - Celularity Inc (0001752828) (Issuer)
4 - Celularity Inc (0001752828) (Issuer)
FLORHAM PARK, N.J., June 03, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity" or the "Company"), a longevity-focused regenerative and cellular medicine company pioneering placental-derived cellular and regenerative therapies, today announced the appointment of Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. In this role, Mr. Gonzalez will oversee global commercial strategy and execution for cenplacel-L, Lifebank and the Company's broader regenerative medicine portfolio, and will report to Robert J. Hariri, M.D., Ph.D., Celularity's Chairman, Chief Executive Officer and Founder. "Rick's appointment comes at an important time for Celularity as we conti
Veteran Financial and M&A Leader Appointed to Integrate Acquisition of Celularity, Scale the Business and Accelerate Growth LANGHORNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Ian Blackman, CPA, as Chief Financial Officer. Mr. Blackman will help to advance the closing of the definitive agreement to license and acquire a portfolio of commercial-stage regenerative biomaterial products from Celularity Inc., ("Celularity")
Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing Licensing and acquiring a diversified suite of 6 established regenerative biomaterial products, most with existing insurance reimbursement, along with three new product 510(k) filings planned for 2026, 2027, and 2028 Experienced commercial team is expected to join NEXGEL, significantly expanding the Company's sales reach and operational capabilities LANGHORNE, Pa., March 10, 2026 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) pr
SC 13D/A - Celularity Inc (0001752828) (Subject)
SC 13G/A - Celularity Inc (0001752828) (Subject)
SC 13D/A - Celularity Inc (0001752828) (Subject)
FLORHAM PARK, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a regenerative and cellular medicine company, has issued a Corporate Update to Shareholders from Robert J. Hariri, M.D., Ph.D., Founder, Chairman, and CEO. Dear Shareholders, I am pleased to share recent developments at Celularity, including an update on our commercial-stage advanced biomaterial products business. Let me start by reiterating what we said in our announcement last week, which is that we are resolutely committed to regaining full compliance with Nasdaq's listing requirements. We acknowledge the importance of timely filings and have been diligently working with our new auditi